Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egeberg

Showing results (221-230 of 332) with videos related to

Pageof 34
Sort By:
Journal of Drugs in Dermatology : JDD|June 19, 2020
Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Alexander Egeberg, Giampiero Girolomoni, Steven R Feldman, et al.
The Journal of Dermatological Treatment|October 2, 2023
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeksAlexander Egeberg, Lars Erik Kristensen, Luis Puig, et al.
Journal of the American Academy of Dermatology|October 16, 2016
Ten-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but reduced compared with psoriasisAlexander Egeberg, Lone Skov, Yuki M F Andersen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 12, 2024
Psychological impact on flare patterns and severity of atopic dermatitisMia-Louise Nielsen, Lea K Nymand, Arnau Domenech Pena, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 30, 2024
Characterization of patients with atopic dermatitis based on flare patterns and severity of disease: A Danish population-based studyMia-Louise Nielsen, Lea K Nymand, Arnau Domenech Pena, et al.
Acta Dermato-Venereologica|November 21, 2023
Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide StudyNikolai Loft, Alexander Egeberg, Daniel Isufi, et al.
The British Journal of Dermatology|June 11, 2026
Risk of major adverse cardiovascular events in patients with chronic hand eczema from the Danish National Patient RegisterMaria O Christensen, Johan Sieborg, Ida Vittrup, et al.
Dermatology and Therapy|April 22, 2024
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60Alexander Egeberg, Jason E Hawkes, Najwa Somani, et al.
Rheumatology (Oxford, England)|August 30, 2023
Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort studyRebekka L Hansen, Tanja S Jørgensen, Alexander Egeberg, et al.
JAMA Dermatology|April 7, 2021
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With PsoriasisNikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Pageof 34

Showing results (221-230 of 332) with videos related to

Sort By:
Pageof 34
Journal of Drugs in Dermatology : JDD|June 19, 2020
Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Alexander Egeberg, Giampiero Girolomoni, Steven R Feldman, et al.
The Journal of Dermatological Treatment|October 2, 2023
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeksAlexander Egeberg, Lars Erik Kristensen, Luis Puig, et al.
Journal of the American Academy of Dermatology|October 16, 2016
Ten-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but reduced compared with psoriasisAlexander Egeberg, Lone Skov, Yuki M F Andersen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 12, 2024
Psychological impact on flare patterns and severity of atopic dermatitisMia-Louise Nielsen, Lea K Nymand, Arnau Domenech Pena, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 30, 2024
Characterization of patients with atopic dermatitis based on flare patterns and severity of disease: A Danish population-based studyMia-Louise Nielsen, Lea K Nymand, Arnau Domenech Pena, et al.
Acta Dermato-Venereologica|November 21, 2023
Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide StudyNikolai Loft, Alexander Egeberg, Daniel Isufi, et al.
The British Journal of Dermatology|June 11, 2026
Risk of major adverse cardiovascular events in patients with chronic hand eczema from the Danish National Patient RegisterMaria O Christensen, Johan Sieborg, Ida Vittrup, et al.
Dermatology and Therapy|April 22, 2024
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60Alexander Egeberg, Jason E Hawkes, Najwa Somani, et al.
Rheumatology (Oxford, England)|August 30, 2023
Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort studyRebekka L Hansen, Tanja S Jørgensen, Alexander Egeberg, et al.
JAMA Dermatology|April 7, 2021
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With PsoriasisNikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, et al.
Pageof 34